More than 95% of chronic myeloid leukemia (CML) and 20%-30% of acute lymphoblastic leukemia (ALL) patients express the fusion protein BCR-ABL1. The first-generation ABL tyrosine kinase inhibitor (TKI) Gleevec (imatinib) has significantly enhanced the prognosis of CML patients.
Nanjing Zaiming Pharmaceutical Co. Ltd. has described proteolysis targeting chimera (PROTACs) compounds comprising of E3 ubiquitin ligase cereblon (CRBN)-binding moiety coupled to probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α)-targeting moiety through a linker reported to be useful for the treatment of cancer.
The University of Kentucky has prepared and tested mithramycin oxime derivatives reported to be useful for the treatment of cancer and neurological disorders.
Beijing Normal University presented data on fibroblast activation protein (FAP)-targeting agents containing a nitroimidazole moiety, [68Ga]/[177Lu]AAZTA-NI-FAPI-04, being developed for the potential imaging and treatment of cancer.
Scientists from the University of Wisconsin-Madison have reported the discovery of novel carbonic anhydrase IX (CAIX) radioligands for molecular imaging in clear cell renal cell carcinoma (ccRCC).
Researchers from Eli Lilly & Co. presented the discovery and preclinical characterization of a novel protein tyrosine kinase 7 (PTK7)-targeting antibody-drug conjugate (ADC), LY-4175408, being developed for the treatment of cancer.
RSS
